Genesis RMN / GenesisX

Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.

Genesis RMN / GenesisX's price is not publicly disclosed. DEPLOY has no verified price on record for Genesis RMN / GenesisX from Stereotaxis. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.

Yes. Genesis RMN / GenesisX is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.

Genesis RMN / GenesisX is made by Stereotaxis, based in St. Louis, MO, USA, founded in 1990.

2 verified deployments of Genesis RMN / GenesisX are on the DEPLOY registry, including at Global (multiple sites), United States.

Genesis RMN / GenesisX is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.

Genesis RMN / GenesisX has 2 regulatory records on the DEPLOY registry: FDA 510(k) clearance, cleared; FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.

On the DEPLOY registry, comparable surgical robots to Genesis RMN / GenesisX include da Vinci (and Ion), Edge Multi-Port Surgical Robot, Edison Histotripsy System, Stryker Mako SmartRobotics.

Genesis RMN / GenesisX and da Vinci (and Ion) (Intuitive Surgical · 15 deployments) are both surgical robots on the DEPLOY registry. Genesis RMN / GenesisX has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.

On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Genesis RMN / GenesisX ranks in roughly the top 51% of surgical models tracked by the registry.

Genesis RMN / GenesisX is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.

Genesis RMN / GenesisX has 1 active incident on record in the DEPLOY registry. 1 incident on record (1 minor). Most recent: Apr 2026. Retracted incidents are excluded from this count.